The location distribution of the primary and recurrent bladder tumours was studied in 417 patients. The authors decided that the ureteral orifices, the lateral walls are the most common places of primary superficial bladder tumours. The favoured places of the primary invasive bladder tumours are the posterior walls. They found not so much disparity between the site of primary and recurrent invasive bladder tumours, but the difference between the site of the primary and recurrent superficial bladder tumours is remarkable. They decided, according to their patients material, that the recurrent superficial bladder tumours take places more frequently on the posterior walls, the dome and the anterior walls. The explanation of this phenomenon may be the tumour cells implantation during the TUR. The authors survived all the other processes can yield the local and distant recurrent bladder tumours and understanding of this processes can result in a better understanding of the location distribution of the recurrent bladder tumours on the one hand and it can help us to avoid or decrease the recurrences on the other hand.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Predictive value of Bladder EpiCheck in detecting residual tumor before second TUR for non-muscle-invasive bladder cancer.
World J Urol
January 2025
Department of Urology, University of Health Sciences, Bagcilar Training and Research Hospital, Istanbul, 34200, Turkey.
Purpose: As Bladder EpiCheck (BE) is a promising urinary biomarker for diagnosis and follow up of non-muscle-invasive bladder cancer (NMIBC), there are no studies evaluated this tool for second transurethral resection (TUR) indication. We aim to evaluate the performance of BE in predicting residual tumor before second TUR in NMIBC and its effects on clinical decision making.
Methods: A total of 50 patients who were diagnosed with NMIBC and indicated for a second TUR were included in the study prospectively.
Development and external validation of a model to predict recurrence in patients with non-muscle invasive bladder cancer.
Front Immunol
January 2025
School of Nursing, Zunyi Medical University, Zunyi, China.
Background: Most patients initially diagnosed with non-muscle invasive bladder cancer (NMIBC) still have frequent recurrence after urethral bladder tumor electrodesiccation supplemented with intravesical instillation therapy, and their risk of recurrence is difficult to predict. Risk prediction models used to predict postoperative recurrence in patients with NMIBC have limitations, such as a limited number of included cases and a lack of validation. Therefore, there is an urgent need to develop new models to compensate for the shortcomings and potentially provide evidence for predicting postoperative recurrence in NMIBC patients.
View Article and Find Full Text PDFDevelopment and validation of a glycolysis-associated gene signature for predicting the prognosis, immune landscape, and drug sensitivity in bladder cancer.
Front Immunol
January 2025
Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Background: Bladder cancer (BCa) is one of the most common malignancies worldwide, and its prognostication and treatment remains challenging. The fast growth of various cancer cells requires reprogramming of its energy metabolism using aerobic glycolysis as a major energy source. However, the prognostic and therapeutic value of glycolysis-related genes in BCa remains to be determined.
View Article and Find Full Text PDFCharacterization of tumor epigenetic aberrations is integral to understanding the mechanisms of tumorigenesis and provide diagnostic, prognostic, and predictive information of high clinical relevance. Among the different tumor-associated epigenetic signatures, 5 methyl-cytosine (5mC) and 5-hydroxymethylcytosine (5hmC) are the two most well-characterized DNA methylation alterations linked to cancer pathogenesis. 5hmC has a tissue-specific distribution and its abundance is subjected to changes in tumor DNA, making it a promising biomarker.
View Article and Find Full Text PDFNeurofibroma of bladder: A case report and literature review.
Urol Case Rep
January 2025
Department of Urology, Shandong Provincial Third Hospital, Shandong University, Jinan, 250012, China.
To improve the understanding and treatment level of urogenital nerve fibroma by sharing the clinical manifestations, imaging features, and pathological characteristics of a case of urogenital nerve fibroma.The patient was a middle-aged male with initial symptoms of painless gross hematuria, bladder irritation, and pelvic mass. Imaging examination showed a bladder mass, and transurethral bladder tumor resection was performed to reduce the tumor.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!